Brexidolart Cutaneous Foam 50g 1%,Brexidolart Schiuma Cutanea 50g 1%,CHIESI FARMACEUTICI SPA

“ACTIVE ingredients: Piroxicam. Excipients: propylene glycol, polysorbate 80, xanthan gum, menthol, methyl p-i drossibenzoato, propyl p-hydroxybenzoic acid, citric acid monohydrate, I know, God hydroxide drops, titanium dioxide, ethanol 96%, purified water. Pr opellente: propane-butane isobutane.
INDICATIONS: painful sensations and inflammatory nature of rheumatic or traumatic art icolazioni, muscles, tendons and ligaments.
CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance or to any of the ingredients listed.
DOSAGE: To dispense foam, shake the container upside down or before use, and then press the valve for a few seconds: the valve provides 1-2 g/sec, which is enough for an area of about 40 cm^2. Use this amount of medicine twice a day.
STORAGE CONDITIONS: Store at temperatures below 25 degrees C; – for the presence of p ropellente, do not expose the preparation to temperatures above 50 gra C; in a pressurized container, there should be no wood, should not be close, even if empty, to heat sources, should not be frozen and should not be exposed to direct sunlight.
WARNINGS: the amount of active substance is absorbed through the skin without reaching iunge, as a rule, concentrations in the body such as to make them valid in vvertenze and the risk of side effects associated with know, mministrazione medications systemically. The use of the product for topical use, especially if prolonged, may lead to sensitization phenomena. If hypersensitivity reactions occur, you should stop treatment and institute appropriate therapy. I l propylene glycol present as an excipient may cause skin irritation. All paraidrossibenzoati are present as excipients can cause allergic reactions (possibly delayed).
INTERACTIONS: Depending on bioavailability and this is extremely unlikely, ch and piroxicam foam displaces other drugs bound to plasmatic proteins. However, physicians should monitor patients taking the drug 10mg/g foam and the drug’s high safety profile to ensure any dosage adjustments are made.
SIDE EFFECTS: Use of the product, especially if prolonged, may lead to symptoms of sensitization and local irritation. Rarely, reactions may occur with urticaria and bronchospasm. In this case, treatment should be stopped. The following dermatitis side effects have also been reported with topical use of piroxicam: contact dermatitis, eczema and photosensitivity skin reactions. Reporting r eaton adverse events that occur after authorization in the building, and this is important because it allows continuous monitoring of the benefit/risk ratio of the drug.
PREGNANCY AND BREAST-FEEDING: As a precautionary measure, use during pregnancy and lactation is not recommended. Possible use is permitted only as directed by a physician, if deemed absolutely necessary.”